Who has invested in iRegene?

Northern Light Venture Capital, Chuangjing Capital, OneHealth Haihe Capital are named among the investors backing iRegene.

iRegene Funding: $42M Raised, Series B (2025)

iRegene funding overview

iRegene is based in Wuhan, Hubei, China. iRegene has raised $42M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in September 2025. The round record for iRegene runs through 2025; nothing later has been disclosed. Investors on record include Northern Light Venture Capital, Chuangjing Capital, OneHealth Haihe Capital. 3 distinct backers are named across the disclosed rounds.

iRegene at a glance

Total raised: $42M
Latest round: Series B
Latest round date: September 2025
Headquarters: Wuhan, Hubei, China
Notable investors: Northern Light Venture Capital, Chuangjing Capital, OneHealth Haihe Capital

Frequently asked about iRegene funding

How much has iRegene raised?: iRegene has raised $42M in total disclosed funding across the rounds on record.
Who has invested in iRegene?: Northern Light Venture Capital, Chuangjing Capital, OneHealth Haihe Capital are named among the investors backing iRegene.
What was the latest iRegene funding round?: The most recent disclosed round is a Series B, announced in September 2025.
Where is iRegene based?: iRegene is based in Wuhan, Hubei, China.
When did iRegene last raise?: The last disclosed iRegene round closed in September 2025 at Series B.

Totals shown for iRegene aggregate every disclosed round on file. To see how that compares, browse the companies in Wuhan and the investors behind them below.

iRegene Funding: $42M Raised, Series B (2025)

iRegene funding overview

iRegene at a glance

Frequently asked about iRegene funding

Companies related to iRegene (27)

Browse related funding lists (4)